logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
NRx Pharmaceuticals, Inc.
(NRXP)
ZYESAMI
Results of a review conducted by DSMB in patients with critical COVID-19 respiratory failure who were enrolled in the ACTIV-3b (TESICO) study of ZYESAMI were reported on May 25, 2022. The DSMB recommended stopping further randomization to ZYESAMI due to ZYESAMI not meeting the futility guidelines outlined by the pre-approved analytical plan.
-
-
05/26/2022
AIM ImmunoTech Inc.
(AIM)
Ampligen
After at least 12 weeks of Ampligen treatment, four patients with new onset Myalgic encephalomyelitis/chronic fatigue syndrome, following acute COVID-19, experienced a reduction in fatigue- reported on May 18, 2022.
An IND application to be submitted with the FDA for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions
-
05/19/2022
SIMCERE PHARMA
SIM0417 to treat Covid-19
Clinical trial approval from National Medical Products Administration in China was received for SIM0417 for the treatment of Covid-19-reported on May 17, 2022.
-
-
05/18/2022
Synairgen plc
(SNG.L)
SNG001
Phase 3 SPRINTER study of SNG001 did not meet the primary endpoints of discharge from hospital and recovery- reported on 21 February 2022.
-
-
05/17/2022
Akston Biosciences Corporation
AKS-452- COVID-19 vaccine
Phase 2 study evaluating AKS-452 as a Covid-19 booster vaccine was initiated- reported on May 12, 2022.

Phase 2/3 study of AKS-452 was initiated in India-reported on Apr.7, 2022.

Regulatory clearance was received in the Netherlands to conduct Phase 2 study of AKS-452 as a booster dose of Covid-19 vaccine- reported on March 31, 2022.
Submission for Emergency Use Authorization (EUA) is expected by Q3 2022.
-
05/13/2022
SaNOtize Research and Development
Nitric oxide nasal spray
Results from a retrospective study showed that nitric oxide nasal spray is effective in preventing COVID-19 infection after high-risk exposure- reported on May 11, 2022.
-
-
05/12/2022
Vaxart, Inc.
(VXRT)
Oral tablet COVID-19 vaccine
Phase 2 study of Oral Tablet COVID-19 Vaccine was initiated on October 26, 2021.
Data from the dose selection portion of the two part dose-ranging and preliminary efficacy Phase II trials of oral tablet COVID-19 vaccine candidate are expected in the third quarter of 2022.
-
05/11/2022
Previous Records

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Biotech Stocks Facing FDA Decision In June 2022

Biotech Stocks Facing FDA Decision In June 2022
Biotech Stocks Facing FDA Decision In March 2022

Biotech Stocks Facing FDA Decision In March 2022
Biotech Stocks Facing FDA Decision In February 2022 non small cell lung cancer chemotherapy

Biotech Stocks Facing FDA Decision In February 2022
Editors Pick
Asweets Recalls Wonder & Wise Activity Tables
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children.
Alibaba Q4 Loss Sharply Widens
Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies.
Macy's Boosts FY22 Adj. EPS Outlook As Q1 Results Top Estimates
Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Latest Updates on COVID-19
Read More
COVID-19: Drugs in Development
Copyright © 2022 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap